about
Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesGolimumab for the treatment of ulcerative colitis.Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cellsInvolvement of neutrophil hyporesponse and the role of Toll-like receptors in human immunodeficiency virus 1 protectionPrevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials.Comparison of Screening Dilution and Automated Reading for Antinuclear Antibody Detection on HEP2 Cells in the Monitoring of Connective Tissue Diseases.Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus ErythematosusUp-regulation of TLR2 and TLR4 in dendritic cells in response to HIV type 1 and coinfection with opportunistic pathogensMemory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice.Golimumab pharmacokinetics in ulcerative colitis: a literature reviewMethotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.Management of cytomegalovirus infection in inflammatory bowel diseases.Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage.Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.Pharmacokinetics in IBD: ready for prime time?Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.The Genotyping Resistance Profile of the Pol Gene Detected in Blood of Newly Diagnosed HIV-Positive Men Is Durably Archived in the Gut Whatever the Time of Initiation of cART.Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations.Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses.Triggering Intracellular Receptors for Vaccine Adjuvantation.Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.Humoral responses against HIV in male genital tract: role in sexual transmission and perspectives for preventive strategies.Vaccination against Salmonella Infection: the Mucosal Way.Zinc-Stabilized Chitosan-Chondroitin Sulfate Nanocomplexes for HIV-1 Infection Inhibition Application.Ternary polysaccharide complexes: Colloidal drug delivery systems stabilized in physiological media.Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands.Anti-N-methyl-D-aspartate receptor encephalitis after Herpes simplex virus-associated encephalitis: an emerging disease with diagnosis and therapeutic challenges.Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAARTPlasmacytoid dendritic cells and myeloid cells differently contribute to B-cell-activating factor belonging to the tumor necrosis factor superfamily overexpression during primary HIV infection.[Targeting and role of α4β7 integrin in the pathophysiology of IBD and HIV infection].Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity.Secretory IgA as a vaccine carrier for delivery of HIV antigen to M cells.Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis.
P50
Q27013577-A134057A-95FC-408D-B7E3-448873E990A9Q33852257-4DCEC8CD-F159-4249-8CEE-BF9F15CD829BQ33855697-4875A368-100C-4B00-9CE8-30C696A2030AQ34998132-9997DE55-80CB-4521-83D3-B68C6B14DCDCQ35192491-506C26C2-E10F-4059-BA3F-8DD88417466CQ35501623-B82FFA9F-6B92-4562-8C6B-019B95AC10B5Q36029496-83581115-DECC-49D7-A1B1-5E1578F38EADQ36134326-916D4A41-E804-4BAD-8D0A-7ECB2C8C8151Q36352579-181FD3B2-5A9B-4AE5-9B09-96AB7001FF13Q36530142-9C19ADD8-2ABE-411D-AE33-B2AF93FA4D5EQ37671983-D3BBAA4B-F215-4392-A556-F09559DEA3F6Q37703466-D7D1B4F5-26F4-4287-87CE-BE4D40E7700BQ38005883-B294C4D9-156B-432F-AAE0-39913C292577Q38046828-2D7B3757-FDF9-4A78-988D-D0E0B52261BEQ38151142-F8669CAD-3E7F-469D-B7DE-82CACAACC463Q38211991-78D29C79-B8C8-4854-8F8E-389870AB2C22Q38244883-24217F89-1FC3-45B4-A4E8-B0C2000F8438Q38280973-20577E80-0EC2-4973-AA1D-4AD8CB8793DEQ38375046-DAA80440-F1BC-44E7-B119-CAE73B7CB9DCQ38669977-6E20FA98-BE49-4B9C-9522-AEEBD656F11AQ38681918-66A1A1FC-2ACD-418A-A872-68BC2A4F3C7CQ38754324-D8036488-E8C0-4F54-B4E9-F93C7B0033E0Q38825796-227502DB-4378-4FE1-8CF0-BA844C3F17FBQ38913112-1219564D-1FD8-4EA0-B1C8-1ABDB7198FD0Q39077823-1800C87A-8826-44C9-9492-6B57C44CC8F9Q39146058-62D287F7-D5A0-4161-8FA4-F694AAE21D58Q39175362-2CC721C5-9AEE-4587-B7EA-5510C660D12EQ39190370-6597AD77-743F-407E-B7BB-CF7F13C595BEQ39373957-B96465EA-A477-4BEF-946C-3FD3F34B6724Q39563841-D8D40A5A-A898-458D-98A6-FD75E8222C6EQ40162828-291AE445-3FB1-40F4-9AA6-C177C7A120C6Q40353193-00A1EC1A-A553-4B4B-87D1-40DE9ED20ED8Q40458917-41EF9811-A71B-4A9D-B5D2-19BB4129C0B8Q40630115-ABC7D596-2DF4-49BA-96D1-378765C01899Q40699445-E4C7A552-634A-4CC5-9F1E-7812C0D8D809Q40913949-8CE9CCDA-8A99-4FD7-89D8-1E251149EE37Q40946143-EBBBA8C6-5B3F-4470-8E21-52B1124B41EFQ40977240-79F7EBAC-BF35-41F4-8A86-7E473E377DB6Q41654336-C881B708-2C78-4C97-B0B3-0B36BF4C019AQ42707435-6771751E-B7B8-43E2-8B3D-F3F33EFC69E8
P50
description
researcher ORCID ID = 0000-0002-8830-4273
@en
wetenschapper
@nl
name
Stéphane Paul
@ast
Stéphane Paul
@en
Stéphane Paul
@nl
type
label
Stéphane Paul
@ast
Stéphane Paul
@en
Stéphane Paul
@nl
prefLabel
Stéphane Paul
@ast
Stéphane Paul
@en
Stéphane Paul
@nl
P31
P496
0000-0002-8830-4273